GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (FRA:SG7) » Definitions » Shiller PE Ratio

Sage Therapeutics (FRA:SG7) Shiller PE Ratio : (As of Jun. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sage Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Sage Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Shiller PE Ratio Chart

Sage Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sage Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sage Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Sage Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sage Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sage Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sage Therapeutics's Shiller PE Ratio falls into.



Sage Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sage Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Sage Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.656/131.7762*131.7762
=-1.656

Current CPI (Mar. 2024) = 131.7762.

Sage Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.229 100.560 -0.300
201409 -0.388 100.428 -0.509
201412 -0.391 99.070 -0.520
201503 -0.610 99.621 -0.807
201506 -0.802 100.684 -1.050
201509 -0.748 100.392 -0.982
201512 -0.909 99.792 -1.200
201603 -0.871 100.470 -1.142
201606 -0.961 101.688 -1.245
201609 -1.025 101.861 -1.326
201612 -1.422 101.863 -1.840
201703 -1.421 102.862 -1.820
201706 -1.673 103.349 -2.133
201709 -1.653 104.136 -2.092
201712 -1.479 104.011 -1.874
201803 -1.362 105.290 -1.705
201806 -0.308 106.317 -0.382
201809 -2.254 106.507 -2.789
201812 -2.971 105.998 -3.694
201903 -2.982 107.251 -3.664
201906 -2.903 108.070 -3.540
201909 -3.160 108.329 -3.844
201912 -2.925 108.420 -3.555
202003 -2.208 108.902 -2.672
202006 -2.335 108.767 -2.829
202009 -1.723 109.815 -2.068
202012 14.952 109.897 17.929
202103 -1.378 111.754 -1.625
202106 -1.519 114.631 -1.746
202109 -1.879 115.734 -2.139
202112 -1.876 117.630 -2.102
202203 -1.880 121.301 -2.042
202206 -2.015 125.017 -2.124
202209 -2.333 125.227 -2.455
202212 -2.332 125.222 -2.454
202303 -2.298 127.348 -2.378
202306 -2.474 128.729 -2.533
202309 -3.158 129.860 -3.205
202312 -0.495 129.419 -0.504
202403 -1.656 131.776 -1.656

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sage Therapeutics  (FRA:SG7) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Sage Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sage Therapeutics (FRA:SG7) Business Description

Traded in Other Exchanges
Address
215 First Street, Cambridge, MA, USA, 02142
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

Sage Therapeutics (FRA:SG7) Headlines

No Headlines